1SiegelRL, MillerKD, JemalA. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1): 7-30.
2ChenW, ZhengR, BaadePD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
3ChopraS, RashidP. Management of castration-resistant (advanced) prostate cancer (CRPC): rationale, progress and future directions[J].Aust Fam Physician, 2015, 44(5): 302-305.
4MolinaA, BelldegrunA. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling[J]. J Urol, 2011, 185(3):787-794.
5ScherHI, FizaziK, SaadF, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy[J]. N Engl J Med, 2012, 367(13):1187-1197.
6PientaKJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer[J]. Semin Oncol, 2001, 28(4Suppl 15):3-7.
7PallerCJ, AntonarakisES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer[J]. Drug Des Devel Ther, 2011, 5:117-124.
8BertholdDR, PondGR, SobanF, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study[J]. J Clin Oncol, 2008, 26(2):242-245.
9OudardS, BanuE, BeuzebocP, et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer[J]. J Clin Oncol, 2005, 23(15):3343-3351.
10KantoffPW, HiganoCS, ShoreND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer[J]. N Engl J Med, 2010, 363(5):411-422.